John Wilson
Director/Board Member bij MARKER THERAPEUTICS, INC.
Vermogen: 7 M $ op 31-03-2024
Profiel
John R.
Wilson is the founder.
He founded Wilson Wolf Manufacturing Corp.
in 1998, where he holds the title of Chief Executive Officer.
He also founded AlloVir, Inc. in 2013, where he served as an Independent Non-Executive Director from 2018 to 2022.
Mr. Wilson is also the founder of Marker Cell Therapy, Inc. Currently, he is working as an Independent Director at Marker Therapeutics, Inc. since 2018.
In the past, he worked at Cellex Biosciences, Inc. as a Principal.
Mr. Wilson completed his undergraduate education at Hamline University and the University of Minnesota.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ALLOVIR INC
4.70% | 31-12-2023 | 5 355 877 ( 4.70% ) | 4 M $ | 31-03-2024 |
| 06-06-2023 | 781 200 ( 8.77% ) | 3 M $ | 31-03-2024 |
Actieve functies van John Wilson
| Bedrijven | Functie | Begin |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Director/Board Member | 17-10-2018 |
Wilson Wolf Manufacturing Corp.
 Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Chief Executive Officer | 01-01-1998 |
Eerdere bekende functies van John Wilson
| Bedrijven | Functie | Einde |
|---|---|---|
| ALLOVIR, INC. | Founder | 01-01-2018 |
| Cellex Biosciences, Inc. | Corporate Officer/Principal | - |
Marker Cell Therapy, Inc.
 Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Chief Executive Officer | - |
Opleiding van John Wilson
| Hamline University | Undergraduate Degree |
| University of Minnesota | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
| Cellex Biosciences, Inc. | Distribution Services |
Wilson Wolf Manufacturing Corp.
Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Health Technology |
Marker Cell Therapy, Inc.
Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Commercial Services |
